The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

Launched by UNIVERSITY OF ALEPPO · Nov 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called 5-fluorouracil (5-FU) to treat basal cell carcinoma (BCC), which is a common type of skin cancer. The researchers want to find out how safe and effective this treatment is for different types of BCC, specifically superficial and small nodular lesions. The trial will take place at Aleppo University Hospital and will involve patients who are between 5 and 90 years old. To be eligible, participants must have a superficial lesion or a nodular lesion smaller than 1.5 cm and must be willing to volunteer for the study.

Participants in this study can expect to receive 5-FU directly into their skin lesions. After the treatment, they will be monitored for 12 months to see how well the medication works and if there are any side effects. It’s important to note that patients with larger nodular lesions (greater than 1.5 cm) or ulcerated lesions cannot take part in this trial. The aim is to gather valuable information that can help improve treatment options for people with BCC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 5 Years to 90 Years (Child, Adult, Older Adult).
• • Volunteer to participate in study
• • Superficial lesion
• • Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period.
• Exclusion Criteria:
• • Ulcerative.
• • Nodular lesion (x ≥ 1.5 cm)